Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced statistically significant data from the 16-week ...

Nektar Therapeutics (NASDAQ:NKTR) saw its stock soar 140% following promising Phase 2b trial results for its experimental treatment rezpegaldesleukin in moderate-to-severe atopic dermatitis. The ...

An EASI score is calculated based on the area of eczema lesions and how severe they are. A score of 0 means clear or no eczema, 0.1 to 1.0 means almost clear, ...

Easi-Set Worldwide, a subsidiary of Smith-Midland Corporation (NASDAQ:SMID), is excited to announce a new licensing agreement with Infrastructure Precast Inc. (ICast) of Kentucky. Under this ...

A literature review has confirmed that the Eczema Area and Severity Index (EASI) is an effective tool for measuring the severity and extent of atopic dermatitis (AD) -- including in patients with ...

EASI can immediately help the DEA maximize its ability to discriminate between different strains of emerging synthetic drugs." Jackson said he believes there is no time to waste in improving ...

Easi, which was founded by Jie (Jason) Shen, was majority owned by a Docklands-based woman called Yan (Linda) Liu, who bought the stake from Mr Shen in 2019. Mr Shen retained 23 per cent.